- Home
- NP vs CPRX Comparison
NP vs CPRX Comparison
Compare NP & CPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NP | CPRX |
|---|---|---|
| Founded | 2017 | 2002 |
| Country | United States | United States |
| Employees | 60 | N/A |
| Industry | Specialty Insurers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.4B | 3.9B |
| IPO Year | N/A | 2006 |
Fundamental Metrics
Financial Performance| Metric | NP | CPRX |
|---|---|---|
| Price | $31.25 | $31.49 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 12 | 1 |
| Target Price | $28.17 | ★ $35.00 |
| AVG Volume (30 Days) | 936.6K | ★ 2.0M |
| Earning Date | 04-22-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 28.24 |
| EPS | N/A | ★ 0.50 |
| Revenue | N/A | ★ $119,072,803.00 |
| Revenue This Year | $25.84 | $9.20 |
| Revenue Next Year | $15.80 | $10.51 |
| P/E Ratio | ★ N/A | $62.98 |
| Revenue Growth | N/A | ★ 16.39 |
| 52 Week Low | $14.78 | $19.05 |
| 52 Week High | $34.61 | $32.56 |
Technical Indicators
Market Signals| Indicator | NP | CPRX |
|---|---|---|
| Relative Strength Index (RSI) | 54.07 | 70.31 |
| Support Level | $23.62 | $31.25 |
| Resistance Level | $31.63 | $32.56 |
| Average True Range (ATR) | 1.53 | 0.04 |
| MACD | -0.25 | -0.05 |
| Stochastic Oscillator | 39.19 | 86.96 |
Price Performance
Historical ComparisonAbout NP Neptune Insurance Holdings Inc.
Neptune Insurance Holdings Inc is a high-growth, profitable, data-driven MGA that offers residential and commercial insurance products, including primary flood insurance, excess flood insurance and parametric earthquake insurance, distributed through a nationwide network of agencies in the United States. The company underwrites and administers the issuance of insurance policies on behalf of a diverse panel of insurance and reinsurance companies and does not take any balance sheet insurance risk or have claims handling responsibility relating to the policies it sells.
About CPRX Catalyst Pharmaceuticals Inc.
Catalyst Pharmaceuticals Inc is a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing, developing, and commercializing novel high-quality medicines for patients living with rare and difficult to treat diseases. The Company sells three commercial stage drug products, FIRDAPSE (amifampridine), AGAMREE (vamorolone), and FYCOMPA (perampanel). The Company is currently seeking to further expand its product portfolio, with a focus on acquiring the rights to immediately and near-term accretive assets to treat rare (orphan) diseases across therapeutic areas, including clinical-stage opportunities with established proof of concept.